Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer disease

Authors and affiliations
Knut Engedal: Norwegian Centre for Ageing and Health, Vestfold Health Trust, Tønsberg, Norway.
Astrid Bergland: Oslo and Akershus University College of Applied Sciences, Oslo, Norway.
Tron Anders Moger: Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
Oskar Hansson: Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden; Memory Clinic, Skåne University Hospital, Lund and Malmö, Sweden.
Anne Marit Mengshoel: Department of Health Sciences, University of Oslo. Norway.

Corresponding author:
Gro Gujord Tangen, Department of Health Sciences, University of Oslo, P.O. Box 1089 Blindern, 0317 Oslo, Norway. Fax number: 00 47 22 84 50 91, Tel nr: 00 47 22 84 53 71.
E-mail: g.g.tangen@medisin.uio.no

Keywords: Spatial navigation, cognition, Alzheimer, mild cognitive impairment, subjective cognitive impairment
Abstract

**Background:** Impaired spatial navigation is an early sign of Alzheimer disease (AD), but this can be difficult to assess in clinical practice. We examined how the performance on the Floor Maze Test (FMT), which combines navigation with walking, differed between patients with subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and mild AD. We also explored if there was a significant relationship between the FMT and the cognitive tests or sociodemographic factors.

**Methods:** The study included 128 patients from a memory clinic classified as having SCI (n = 19), MCI (n = 20), and mild AD (n = 89). Spatial navigation was assessed by having the patients walk through the FMT, a two-dimensional maze. Both timed measures and number of errors were recorded. Cognitive function was assessed by the Word List Memory test, the Clock Drawing Test, the Trail Making Tests (TMT) A and B, and the Mini Mental Status Examination (MMSE).

**Results:** The patients with MCI were slower than those with SCI, while the patients with mild AD more frequently completed the FMT with errors or gave up than the patients with MCI. Performance on the FMT was significantly associated with executive function (measured by TMT–B).

**Conclusions:** The performances on the FMT worsened with increasing severity of cognitive impairment, and the FMT was primarily associated with executive function. The explained variance was relatively low, which may indicate that the standard cognitive test battery does not capture impairments of spatial navigation.
Introduction

Independent mobility in society requires not only sufficient motor function, but also the ability to navigate in both familiar and unfamiliar surroundings. Spatial navigation involves both route-planning and way-finding, and can be defined as the ability to determine and maintain a route from one place to another (Gallistel, 1990). Failure in spatial navigation may therefore lead to topographical disorientation and getting lost. Navigational skills decline with age (Cushman et al., 2008), and this decline is even more pronounced in individuals with Alzheimer disease (AD), where spatial disorientation is considered one of the earliest signs of the disease (Pai and Jacobs, 2004). Studies have found that approximately 50% of community-dwelling people with AD experience navigational impairment (deIpolyi et al., 2007; Pai & Jacobs, 2004). This is likely because spatial navigation impairment is related to atrophy of the hippocampus and parahippocampal gyrus (deIpolyi et al., 2007; O'Keefe and Nadel, 1978), where the first neural losses are observed in patients with AD (Braak and Braak, 1991). Loss of confidence in navigational skills is likely to hamper activities of daily living (ADL). This was shown in a study where older drivers with self-perceived navigational impairments reported that they avoided unfamiliar routes and places and drove less than those who experienced no navigational problems (Burns, 1999). Thus, navigational ability is therefore an important issue to address with regard to impact on daily activities, as well as in the light of early identification of AD.

Descriptions of a continuum between healthy ageing and AD involve at-risk states referred to as subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) (Reisberg et al., 2010). MCI is characterized by a measurable decline in cognition, but still largely preserved functional abilities (Winblad et al., 2004), although some decrements in complex ADL are reported (Hesseberg et al., 2013). While MCI has a relatively well-established
position in the continuum between healthy aging and AD, SCI is considered a more heterogeneous condition, where there is no objective evidence of cognitive or functional impairments despite personal concern (Jessen et al., 2010). The risk of cognitive decline and progression to MCI and AD is higher for individuals with SCI than for healthy controls (Reisberg et al., 2010), but the estimated time for progression may be as long as 15 years (Reisberg et al., 2008). It is important to acknowledge that a substantial portion of people with SCI, as well as about half of them with MCI, remain cognitively stable and even cease to worry about their cognitive function. However, studies suggest that changes in spatial abilities occur before patients fill the criteria for AD. In a longitudinal study, visuo-spatial abilities began to decline 3 years prior to a clinical diagnosis of AD (Johnson et al., 2009). In cross-sectional studies navigational impairments have also been reported in patients with MCI (Benke et al., 2013; deIpolyi et al., 2007; Hort et al., 2007), while patients with SCI have shown no impairment of their navigational skills relative to healthy controls (Hort et al., 2007; Kalova et al., 2005). However, literature on spatial navigational abilities in the continuum between healthy and AD is still scarce, and a reason might be that research is hampered by the lack of established consensus on how to conduct assessments of spatial navigation with real-life applicability.

Real-life spatial navigation is continuously and dynamically conducted in complex surroundings, and assessments that are ecologically valid are therefore difficult to perform in both the clinical and research settings. Studies aimed to reflect real-life complexity of spatial navigation have assessed the ability to navigate in hospital settings (Benke et al., 2013; deIpolyi et al., 2007) or in advanced virtual reality (VR) settings (Cushman et al., 2008). In clinical practice however, it is more common to use pencil-and-paper tests, probably because tests using real-life environments consume time and space, and VR equipment is seldom
available. The pencil-and-paper tests typically target visuo-construction and figure copying skills, which do represent one aspect of spatial abilities; however, the relationship between these tests and real-life navigation is not clear (Moffat, 2009). Both the traditional VR-tests and the pencil-and-paper tests lack the multisensory processes related to actual real-life navigation, where we hear, see, and move our bodies in relation to our surroundings. In one study of walking on a treadmill with and without support, the increased postural demands of walking without support was found to influence the performance on a VR-based spatial navigation task in cognitively healthy persons (Lovden et al., 2005). This study by Lovden et al indicates a dual task effect on the way-finding ability during motor activity in healthy people. We suggest that this approach may be useful to detect spatial navigation impairments also in patients with cognitive impairment and dementia.

The Floor Maze Test (FMT) (Sanders et al., 2008), utilizes this approach by combining a 2-dimensional maze task with walking and was presented as a clinical test of spatial navigation with real-life applicability. The combined walking and navigation in the FMT may provide an opportunity to identify navigational impairments at a very early stage of cognitive impairment. It should be kept in mind that spatial navigation is one of several interrelated cognitive domains, and successful navigation requires contributions from other cognitive processes such as visual perception, learning, memory, and executive functions (Moffat, 2009). In a sample of cognitively healthy elderly subjects, the FMT was associated primarily with executive function, as well as memory function (Sanders et al., 2008). Findings from previous studies, using other measures of spatial abilities, have not been consistent regarding the contribution from standard cognitive test batteries, or demographical factors, on performance of navigation tasks (Benke et al., 2013; delpolyi et al., 2007), which leaves a concern that navigational impairments may go undetected.
The FMT is a relatively new test so we believe it is important to develop an understanding of which other cognitive domains contribute to the performance on the FMT. The aims of this study were to explore 1) whether there are any differences with regard to performance on the FMT between patients with SCI and MCI and between patients with MCI and mild AD; and 2) which sociodemographic factors and tests in the routine cognitive test battery used in memory clinics are related to the performance on the FMT.

**Methods**

**Participants**

This cross-sectional study recruited patients from a larger study focused on gait and balance in patients with cognitive impairment (Tangen *et al.*, 2014). For that study, the following inclusion criteria were used: 1) ability to walk without a walking device; 2) be home-dwelling; 3) be able to follow instructions in Norwegian; and 4) have a tentative diagnosis of SCI, MCI, or mild to moderate AD. The exclusion criteria were moderate to severe pain when walking, other dementia disorders, other severe neurological disease, or severe hearing and vision impairment. In this study, moderate AD was an additional exclusion criterion. The patients’ eligibility was determined based on clinical judgment of information from the patients, carers, staff at the memory clinic and medical records. Patients from the Memory Clinic at Oslo University Hospital were consecutively enrolled from January 2011 to August 2012. Furthermore we included seven patients with SCI during November 2013. All patients provided their informed written consent, and the study was approved by the Regional Committee for Medical and Health Research Ethics in the Southeast of Norway.
Demographic and clinical information

All participants were included in the Norwegian Dementia Registry (NDR), and data from this registry and the patients’ medical records were used to obtain the demographic characteristics, medical information, and cognitive assessments. A very experienced geriatric psychiatrist (KE) blinded to the FMT results reviewed all of the tentative diagnoses after the patients’ first visit to the memory clinic. Patients with subjective memory complaints that did not meet the criteria for MCI were classified as having SCI. For the MCI diagnosis, we applied the Winblad criteria: self and/or informant-reported cognitive impairment and one or more results more than 1.5 SD below the normative means in the cognitive test battery, but still having no or minimal functional impairment (Winblad et al., 2004). We used the International Classification of Diseases-10 diagnostic criteria for research to diagnose AD and to determine if the AD status was mild or moderate (patients with the latter were excluded) (World Health Organization, 1993). The assessment of gait speed (10-meter test) was conducted in a quiet corridor at the Memory Clinic, with the patients instructed to walk at their usual pace. Timing began when the patient began to walk and ended when they crossed the 10-meter line.

Cognitive assessments

The Mini Mental Status Examination (MMSE) was used to assess global cognition (Folstein et al., 1975), which can be scored from 0–30, with higher scores indicating better performance. The Trail Making Test (TMT)-A was used to evaluate attention and processing speed, and the TMT-B was used to examine executive function and set-shifting ability (switching between multiple tasks) (Reitan, 1955). Attempts on the TMTs were interrupted after 5 minutes, although patients were allowed to continue if they insisted (no performances exceeding 6 minutes are reported). The Clock Drawing Test (CDT) was utilized to evaluate
visuo-constructive abilities, applying a dichotomized score of correct versus incorrect based on the Shulman scoring system (5 versus ≤4) (Shulman, 2000). The learning aspect of memory was evaluated with the Word List Memory test from the Consortium to Establish a Registry for Alzheimer’s Disease (scored 0–30, where 30 is best) (Fillenbaum et al., 2008).

Floor Maze Test procedure

The FMT was created based on the illustration in the original paper (Sanders et al., 2008); we used a 7 × 10 foot solid dark blue wax cloth with white tape indicating the lines of the maze (Figure 1). The same physical therapist conducted all of the FMT assessments. The patients were positioned at the entry of the maze and then given instructions. Three components of the FMT were timed: 1) planning time (PT), the time from finishing the instructions until the patient started to walk; 2) immediate maze time (IMT), the time spent walking through the maze from entry to exit; and 3) delayed maze time (DMT), the time spent walking through the maze a second time ten minutes after the initial performance, with other walking tests conducted between the two maze walks. Corrections during the walk were counted, and if a patient asked for advice during the walk, the initial instructions were repeated. Two different outcomes were utilized on the FMT: timed performances for the PT, IMT, and DMT and a dichotomous score of error-free performance versus performance with errors or discontinuation of the IMT. Psychometric properties are yet not established for the FMT.

Statistical analysis

Data were analyzed using the IBM SPSS Statistics version 20 (IBM Corp., Armonk, NY, USA) with a 5% level of significance. Group differences on the demographic variables with a normal distribution were analyzed by a one-way analysis of variance, Kruskal-Wallis tests were used for variables with a skewed distribution, and chi-square statistics were used for categorical variables. Comparisons between the patients that were included and omitted from
the regression analyses were conducted by t-tests (age, education and gait speed), by Mann-Whitney U-test (MMSE), and chi-square tests (sex and comorbidities). Data are presented as the mean and SD, the median and first and third quartiles (Q1 and Q3), or as a frequency.

To analyze group differences on the FMT we applied chi-square statistics for the dichotomous variable of error-free vs with-error performances on the IMT and DMT, and we applied Mann-Whitney U-tests to analyze the differences in the timed FMT-components between the SCI and MCI groups and between the MCI and AD groups. Comparisons between the patient groups that were included and omitted from the regression analysis were conducted by t-tests (age, education, and gait speed), a Mann-Whitney U-test (MMSE), and chi-square tests (sex and comorbidities).

The relationship between the FMT and the independent variables were analyzed using multiple regression models. Because the timed performances for the PT, IMT, and DMT had skewed distributions, these variables were log transformed prior to the regression analysis. Correlation analyses were performed to check for collinearity among the independent variables. A multiple linear regression analysis was performed by entering all of the independent variables into the model and performing a manual stepwise backward regression analysis, removing the least significant variables until only the significant variables were left. The regression coefficients and confidence intervals were back transformed by the formula \[\exp(\text{estimate}) - 1\] X 100 %, and are reported as per cent (%). To detect a large effect size (>0.35) with 80% power and a significance level of 0.05 for nine independent variables in the regression analyzes, we estimated that 54 patients would be required, thus we had the necessary sample for these analysis. As this was an exploratory study we did not perform power analyzes for the group comparisons.
Results

As presented in Table 1, 128 patients (69 men; 53.9%) were included: 19 with SCI, 20 with MCI, and 89 with mild AD. The mean (SD) age was 69.8 (8.1) years, and the median (Q1, Q3) MMSE was 26.0 (24, 28). There were no significant differences between the groups with regard to age, sex, or education (\( p > 0.18 \)). Sixteen patients (15 with AD and 1 with SCI, mean (SD) age 71.3 (10.7) and MMSE 23.3 (4.1)) gave up to complete the IMT, and had thus no valid results for the IMT and the DMT, and we also excluded them from the analyses of the PT-component. Five patients did not complete the DMT due to time constraints.

The Fisher’s exact test we ran to evaluate the difference in the percentage of error-free performance on the IMT between the SCI group and the MCI group (84.2% vs. 75 % error-free performance) indicated no significant differences (\( p = 0.70 \)). The percentage of error-free performance did significantly differ (\( \chi^2(1, N = 109) = 7.3, p = 0.007 \)) between the groups of MCI and mild AD (75 % vs. 41.6 % error-free performance).

The SCI group was significantly faster than the MCI group on all three FMT components: PT (\( p = 0.013 \)), IMT (\( p = 0.021 \)), and DMT (\( p = 0.031 \)), and the effect sizes ranged from 0.35 (DMT) to 0.40 (PT). The MCI group was significantly faster than the AD group on the DMT (\( p = 0.02 \)), but not on the PT (\( p = 0.57 \)) or IMT (\( p = 0.12 \)). There were no significant differences regarding time used as a whole between the PT and IMT (\( p = 0.46 \)) or between the IMT and DMT (\( p = 0.39 \)).
In the regression analysis (Table 3) we had one or more missing pieces of data in 30 patients, primarily related to the TMT–B. We did not impute missing data, as these were not missing at random. Thus, the regression analysis consisted of 82 (64%) of the 128 patients enrolled in the study: 15 with SCI, 19 with MCI, and 48 with mild AD. The sample in the regression analysis had significantly higher educational levels ($p = 0.030$), better MMSE scores ($p < 0.001$), and faster walking rates ($p < 0.001$) than those patients who were omitted. There were no significant differences in their age, sex, or medical conditions ($p > 0.05$).

The PT was moderately correlated with the DMT ($r = 0.30, p = 0.002$), but not with the IMT ($r = 0.15, p = 0.11$), while the IMT and DMT were highly correlated ($r = 0.65, p < 0.001$). All independent variables had correlations below $r = 0.7$; therefore, none were omitted from the analyses. In the multiple linear regression analysis, the MMSE was the only variable that was significantly associated with the PT, adjusted $R^2 = 0.04$; $F_{1,80} = 4.0, p = 0.049$) (Table 4). TMT–B was the only variable significantly associated with the IMT (adjusted $R^2 = 0.23$; $F_{1,80} = 25.3, p < 0.001$), and it also contributed to the final DMT (adjusted $R^2 = 0.31$; $F_{2,74} = 18.3, p < 0.001$) model together with the Word List Memory test. The $B$-coefficient of 0.4% indicates that if the performance on the TMT–B increases with 10 seconds, the corresponding change on IMT is 4%. The sociodemographic factors were not significantly associated with any of the three FMT components. The estimated effect size [$f^2 = R^2/(1 - R^2)$] of the multiple regression model was small for the PT ($f^2 = 0.12$), while the IMT ($f^2 = 0.41$) and DMT ($f^2 = 0.56$) effect sizes were large (Cohen 1992).

**Discussion**

In this study, patients with MCI were slower on all the three components of the FMT than the patients with SCI, while the patients with mild AD completed the IMT with errors or gave up
more often than the patients with MCI. Executive function, as measured by the TMT–B, was significantly associated with both the IMT and DMT. None of the sociodemographic variables were significantly associated with the FMT components.

We found few indications of spatial navigation impairments in the SCI group; since all but one of our SCI patients were able to complete the IMT without errors, and the SCI group was also faster than the MCI group on the FMT components. These results are in concordance with previous studies that have reported no deficits in spatial navigation in patients with SCI (Hort et al., 2007; Kalova et al., 2005). We found more deficits of spatial navigation in the patients with mild AD than in those with MCI. This is in line with findings from previous studies (Benke et al., 2013; Cushman et al., 2008; deIpolyi et al., 2007), although studies focused on the subgroups of MCI have found no differences between amnestic MCI (primarily memory impairments) and AD patients regarding spatial navigation (Hort et al., 2007; Laczo et al., 2012). However, the patients in the MCI group were not faster than the patients in the AD group on the PT or IMT. So, the patients in the MCI group were generally able to solve the navigational task, but their performances were slow, which may reflect increased effort to carry out the tasks. This is in line with the idea that the continuum from healthy persons to MCI, and then to AD also involves functional limitations, including spatial skills (Johnson et al., 2009; Benke et al., 2013; Hort et al., 2007). Our results corroborate findings from previous studies that indicate navigational impairments occur before patients fulfill the diagnostic criteria for AD, but they may not be a central feature of SCI.

In this study, we found a significant association between the FMT and the tests in a standard cognitive test battery. Executive function, measured by the TMT-B, was significantly associated with both the IMT and DMT. Memory, measured by the Word List Memory test,
was associated with the DMT, and global cognition (assessed by MMSE) was associated with PT. These findings largely agree with the original study (Sanders et al., 2008), where the executive function and attention factor were related to all three components of the FMT. Our findings also agree with a study where both executive function and memory were predictors of poor performance on a route-learning test in patients with MCI or AD (Benke et al., 2013). Other studies have identified executive function as important for “getting-lost behavior” (assessed by questionnaire) in home-dwelling patients with AD (Chiu et al., 2005). Problem solving and maintaining attention are related to way-finding and spatial abilities, but they are also central features of the executive function (Passini et al., 1995).

Memory was significantly associated with the DMT, but not the IMT, which contrasts with Sanders’ study that found the opposite (Sanders et al., 2008). However, it is reasonable for memory impairments to be more related to the DMT than the IMT in our sample, which is characterized by impaired memory function. It is also interesting to note that our patients devoted the same amount of time to all of the components of the FMT. This stands in contrast to Sanders’ cognitively healthy sample, which spent less time on the IMT component than on PT, and less time on the DMT component than on the IMT, indicating a learning process occurred throughout the test.

The PT and IMT were not correlated, and there was a clear difference in the explained variance between the PT (4%) and the IMT/DMT (23/31%) in our study. This point to two different factors. First, the PT and IMT/DMT measure two different aspects of spatial navigation. There is likely a substantial difference between planning a walk standing at a fixed point and actually executing the planned walk while rotating the map as turns in the maze are made. Second, although we found significant associations between the cognitive
tests and FMT, we should be careful not to overestimate their importance. The explained variance is relatively low, indicating our standard cognitive test battery does not sufficiently capture impairments in spatial navigation.

None of the demographic factors were independently associated with any of the FMT components. Several studies have found an age-effect on navigation, where younger people perform better than those that are older. However, these studies typically compared individuals in their twenties to people 60–80-years old (Cushman et al., 2008; Taillade et al., 2013). Our patients were all between 51 and 83-years old, which may explain why no age-effect was seen in our study. Our results also agree with the results from Benke’s study, where none of the demographic factors (age, sex, and education) were predictors for route-learning performance in patients referred to a memory clinic (Benke et al., 2013).

A shortcoming of this study is that the cross-sectional design prevents us from drawing conclusion related to decline of navigational abilities. Further, all patients were recruited from a memory clinic, and this limits the generalizability of our findings to the populations normally seen by specialist outpatient clinics. In addition, the SCI and the MCI groups were small, and the heterogeneity in these two conditions should lead to a cautious interpretation of the findings regarding group differences. However, recruiting patients from a memory clinic is also a strength of this study, because we have a sample consistently examined with the same diagnostic protocol. We also believe patients with SCI recruited from memory clinics may have a higher risk for future cognitive decline than individuals with SCI in population-based studies.
We acknowledge that even though the FMT involves walking, it is obviously still far from a test of real-life spatial navigation, given the lack of use of landmarks, a limited-sized surface, and only being two-dimensional. However, the FMT consumes little time and is an inexpensive test that does not require advanced equipment, and our study has shown that it is feasible for patients with a mild degree of cognitive impairment. Nevertheless, future studies are needed to validate the FMT against real-life navigational tasks and to provide normative values to increase the interpretability of results.

**Conclusion**

The performance on the FMT worsened with the increasing severity of cognitive impairment. The FMT was associated primarily with executive function and memory; however, the explained variance was relatively low, suggesting the standard cognitive test battery does not capture impaired spatial navigation. Sustained participation in both social and physical activities is important for people with dementia, and therefore we believe it is important to identify those individuals who experience impaired spatial navigation. However, our findings need to be confirmed in future larger cohort studies.

**Conflict of interest**

None.

**Description of authors’ roles**

G.G. Tangen, K. Engedal, A. Bergland, O. Hansson and A.M. Mengshoel contributed to the conception and design of the study. G.G. Tangen and T.A. Moger undertook the analyses. G. G. Tangen made the first draft of the manuscript, and, K. Engedal, A. Bergland, T.A. Moger, O. Hansson and A.M. Mengshoel contributed to revising the manuscript critically for
important intellectual content. All authors contributed and approved the final manuscript before submission.

Acknowledgements

The authors thank the participants for their cooperation in the study.
References


World Health Organization. 1993. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research. World Health Organization, Geneva
Tables and figure legends

Figure 1. The Floor Maze test. The start is indicated by the arrow.
### Table 1. Demographic characteristics of the patients (n = 128)

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>All (n = 128)</th>
<th>SCI (n = 19)</th>
<th>MCI (n = 20)</th>
<th>Mild AD (n = 89)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>128</td>
<td>69.8 (8.1)</td>
<td>69.2 (6.6)</td>
<td>67.3 (7.6)</td>
<td>70.6 (8.4)</td>
<td>0.24a</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>128</td>
<td>69 (53.9%)</td>
<td>11 (57.9%)</td>
<td>7 (35.0%)</td>
<td>51 (57.3%)</td>
<td>0.18b</td>
</tr>
<tr>
<td>Education, mean (SD)</td>
<td>126</td>
<td>13.9 (3.4)</td>
<td>14.8 (3.4)</td>
<td>13.6 (3.3)</td>
<td>13.7 (3.4)</td>
<td>0.38a</td>
</tr>
<tr>
<td>Gait speed, m/s, mean (SD)</td>
<td>128</td>
<td>1.15 (0.22)</td>
<td>1.26 (0.18)</td>
<td>1.20 (0.15)</td>
<td>1.12 (0.24)</td>
<td>0.02a</td>
</tr>
<tr>
<td>Cholinesterase inhibitors, n (%)</td>
<td>126</td>
<td>28 (22.2%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>28 (31.8%)</td>
<td>&lt;0.001b</td>
</tr>
<tr>
<td>Mini Mental Status Exam, median (Q1, Q3)</td>
<td>128</td>
<td>26.0 (24.0, 28.0)</td>
<td>29.0 (29.0, 30.0)</td>
<td>28.0 (26.3, 29.0)</td>
<td>25.0 (22.0, 27.0)</td>
<td>&lt;0.001c</td>
</tr>
<tr>
<td>Word List Memory, mean (SD)</td>
<td>118</td>
<td>14.8 (5.3)</td>
<td>21.9 (3.0)</td>
<td>17.4 (3.9)</td>
<td>12.9 (4.4)</td>
<td>&lt;0.001a</td>
</tr>
<tr>
<td>Clock drawing test, correct n (%)</td>
<td>127</td>
<td>65 (50.8%)</td>
<td>16 (84.2%)</td>
<td>16 (80.0%)</td>
<td>33 (37.1%)</td>
<td>&lt;0.001b</td>
</tr>
<tr>
<td>Trail Making Test-A, median (Q1, Q3)</td>
<td>123</td>
<td>48 (36, 74)</td>
<td>38 (30, 53)</td>
<td>37.5 (30.5, 44.8)</td>
<td>56.5 (40.0, 90.0)</td>
<td>&lt;0.001c</td>
</tr>
<tr>
<td>Trail Making Test-B, median (Q1, Q3)</td>
<td>93</td>
<td>119 (86, 180)</td>
<td>91 (74, 127)</td>
<td>106.5 (85.3, 132.8)</td>
<td>145.0 (104.3, 238.0)</td>
<td>0.002c</td>
</tr>
<tr>
<td>Musculoskeletal disorders, n (%)</td>
<td>128</td>
<td>55 (43.0%)</td>
<td>8 (42.1%)</td>
<td>7 (35.0%)</td>
<td>40 (44.9%)</td>
<td>0.72b</td>
</tr>
<tr>
<td>Cardiovascular disease, n (%)</td>
<td>128</td>
<td>56 (43.8%)</td>
<td>8 (42.1%)</td>
<td>5 (25.0%)</td>
<td>43 (48.3%)</td>
<td>0.16b</td>
</tr>
<tr>
<td>Neurological disease, n (%)</td>
<td>128</td>
<td>16 (12.5%)</td>
<td>3 (15.8%)</td>
<td>2 (10.0%)</td>
<td>11 (12.4%)</td>
<td>0.86b</td>
</tr>
</tbody>
</table>

*One-way analysis of variance; Chi-square test; Kruskal-Wallis test.

SD, standard deviation; (Q1, Q3), 1st and 3rd quartiles; SCI, subjective cognitive impairment; MCI, mild cognitive impairment; AD, Alzheimer disease. p = level of significance.

### Table 2. Group comparisons of the Floor Maze Test performances
<table>
<thead>
<tr>
<th>Completed FMT</th>
<th>SCI n = 18</th>
<th>MCI n = 20</th>
<th>Mild AD n = 74</th>
<th>SCI vs MCI&lt;sup&gt;b&lt;/sup&gt;</th>
<th>MCI vs mild AD&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Planning Time, seconds&lt;sup&gt;a&lt;/sup&gt;</td>
<td>19.5 (12.8, 35.5)</td>
<td>33.5 (21.1, 58.3)</td>
<td>31 (16.0, 53.8)</td>
<td>95.5</td>
<td>0.013&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Immediate Maze Time, seconds&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.0 (14.8, 20.0)</td>
<td>22.5 (18.5, 47.2)</td>
<td>34 (22.3, 73.3)</td>
<td>101.0</td>
<td>0.021&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Delayed Maze Time, seconds&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13.0 (10.5, 22.5)</td>
<td>21.4 (16.1, 30.8)</td>
<td>34.8 (20.8, 72.0)</td>
<td>99.5</td>
<td>0.031&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> median (1<sup>st</sup> quartile, 3<sup>rd</sup> quartile); <sup>b</sup>Mann-Whitney U-test

SCI, subjective cognitive impairment; MCI, mild cognitive impairment; AD, Alzheimer disease; IMT, immediate maze time; FMT, floor maze test. <i>p</i> = level of significance, <i>r</i> = effect size.
Table 3. Simple linear regression analysis between the three Floor Maze Test components (log transformed) and the sociodemographic factors, gait speed, and cognitive assessments.

<table>
<thead>
<tr>
<th></th>
<th>Planning time (n =82)</th>
<th>Immediate Maze Time (n =82)</th>
<th>Delayed Maze Time (n =77)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
<td>95% CI</td>
<td>p</td>
</tr>
<tr>
<td>Age</td>
<td>0.2</td>
<td>-1.9, 2.3</td>
<td>0.853</td>
</tr>
<tr>
<td>Sex (male = 0, female =1)</td>
<td>31.9</td>
<td>-5.1, 83.3</td>
<td>0.097</td>
</tr>
<tr>
<td>Education</td>
<td>-3.2</td>
<td>-7.8, 1.4</td>
<td>0.168</td>
</tr>
<tr>
<td>Gait speed (m/s)</td>
<td>-30.8</td>
<td>-67.5, 47.1</td>
<td>0.334</td>
</tr>
<tr>
<td>Mini Mental Status Examination</td>
<td>-6.4</td>
<td>-12.3, -0.03</td>
<td>0.049</td>
</tr>
<tr>
<td>Word List Memory</td>
<td>-2.8</td>
<td>-5.9, 0.6</td>
<td>0.102</td>
</tr>
<tr>
<td>Clock Drawing Test (incorrect =0, correct =1)</td>
<td>-15.0</td>
<td>-40.4, 21.1</td>
<td>0.362</td>
</tr>
<tr>
<td>Trail Making Test A</td>
<td>0.4</td>
<td>-0.3, 1.2</td>
<td>0.257</td>
</tr>
<tr>
<td>Trail Making Test B</td>
<td>0.2</td>
<td>-0.01, 0.4</td>
<td>0.061</td>
</tr>
</tbody>
</table>

*aUnstandardized coefficients are back transformed by the formula \([\exp(estimate) - 1] \times 100\%\), and reported as per cent (%)..

CI, confidence interval. \(p\) = level of significance
Table 4. Final multiple regression models of the associations between the three Floor Maze Test components (log transformed) and independent variables: cognitive tests, sociodemographic factors, and gait speed

<table>
<thead>
<tr>
<th></th>
<th>Planning time (n = 82) Adjusted $R^2 = 0.04$</th>
<th>Immediate Maze Time (n = 82) Adjusted $R^2 = 0.23$</th>
<th>Delayed Maze Time (n = 77) Adjusted $R^2 = 0.31$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$B^a$ 95% CI  $p$</td>
<td>$B^a$ 95% CI  $p$</td>
<td>$B^a$ 95% CI  $p$</td>
</tr>
<tr>
<td>Mini Mental Status Examination</td>
<td>-6.4, -12.3, -0.1  0.049</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Word List Memory</td>
<td></td>
<td></td>
<td>-3.6, -6.5, -0.6  0.018</td>
</tr>
<tr>
<td>Trail Making Test B</td>
<td>0.4, 0.3, 0.6 $&lt;$0.001</td>
<td>0.4, 0.2, 0.6 $&lt;$0.001</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ Unstandardized coefficients are back transformed by the formula $[\exp(\text{estimate}) - 1] \times 100\%$, and reported as per cent (%).

CI, confidence interval. Variables age, sex, education, gait speed, Clock Drawing Test, and Trail Making Test-A did not contribute to any of the final models. $p$ =level of significance.